Mitochondrial targeted therapy with elamipretide (MTP-131) as an adjunct to tumor necrosis factor inhibition for traumatic optic neuropathy in the acute setting.
MouseTBIUnspecifiedC57BL/6Jn = n = 5 per group across 5 groups, 25 mice totalIntravitreal and subcutaneousIntravitreal MTP-131 100 nM in 1.3 microlitres; subcutaneou…Intravitreal MTP-131 15 minutes after injury; subcutaneous dosing on days 0 to…
Model: Sonication-induced traumatic optic neuropathy of the left optic nerve
Intravitreal MTP-131 with subcutaneous etanercept and MTP-131 increased retinal ganglion cell survival by 21 per cent versus PBS controls, with no synergy between etanercept and MTP-131.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.